Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | isocitrate dehydrogenase 1 (NADP+), soluble | Starlite/ChEMBL | No references |
Homo sapiens | glucagon-like peptide 1 receptor | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Loa Loa (eye worm) | pigment dispersing factor receptor c | glucagon-like peptide 1 receptor | 463 aa | 388 aa | 25.8 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | thymidylate kinase, putative | 0.0145 | 1 | 1 |
Echinococcus multilocularis | thymidylate kinase | 0.0145 | 1 | 1 |
Wolbachia endosymbiont of Brugia malayi | thymidylate kinase | 0.0145 | 1 | 0.5 |
Trypanosoma cruzi | UMP-CMP kinase, mitochondrial, putative | 0.0057 | 0.3006 | 0.3006 |
Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.3261 | 0.3261 |
Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.006 | 0.3261 | 0.3261 |
Chlamydia trachomatis | thymidylate kinase | 0.0145 | 1 | 0.5 |
Schistosoma mansoni | thymidylate kinase | 0.0145 | 1 | 1 |
Leishmania major | hypothetical protein, conserved | 0.0057 | 0.3006 | 0.3006 |
Treponema pallidum | thymidylate kinase (tmk) | 0.0145 | 1 | 0.5 |
Mycobacterium tuberculosis | Thymidylate kinase Tmk (dTMP kinase) (thymidylic acid kinase) (TMPK) | 0.0145 | 1 | 1 |
Trypanosoma cruzi | UMP-CMP kinase, mitochondrial, putative | 0.0057 | 0.3006 | 0.3006 |
Entamoeba histolytica | Thymidylate kinase, putative | 0.0145 | 1 | 0.5 |
Brugia malayi | latrophilin 2 splice variant baaae | 0.0041 | 0.1751 | 0.1751 |
Schistosoma mansoni | thymidylate kinase | 0.0145 | 1 | 1 |
Giardia lamblia | CDC8 | 0.0145 | 1 | 0.5 |
Schistosoma mansoni | hypothetical protein | 0.0041 | 0.1751 | 0.1751 |
Trypanosoma brucei | thymidylate kinase, putative | 0.0145 | 1 | 1 |
Trypanosoma cruzi | thymidylate kinase, putative | 0.0145 | 1 | 1 |
Plasmodium falciparum | thymidylate kinase | 0.0145 | 1 | 1 |
Plasmodium vivax | thymidylate kinase, putative | 0.0145 | 1 | 1 |
Schistosoma mansoni | hypothetical protein | 0.0145 | 1 | 1 |
Echinococcus granulosus | thymidylate kinase | 0.0145 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0041 | 0.1751 | 0.1751 |
Leishmania major | thymidylate kinase-like protein | 0.0145 | 1 | 1 |
Trichomonas vaginalis | thymidylate kinase, putative | 0.0145 | 1 | 0.5 |
Mycobacterium leprae | probable thymidylate kinase Tmk (dTMP KINASE) (THYMIDYLIC ACID KINASE) (TMPK) | 0.0145 | 1 | 0.5 |
Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.006 | 0.3261 | 0.3261 |
Trichomonas vaginalis | thymidylate kinase, putative | 0.0145 | 1 | 0.5 |
Trypanosoma brucei | thymidylate kinase, putative | 0.0145 | 1 | 1 |
Toxoplasma gondii | thymidylate kinase | 0.0145 | 1 | 1 |
Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.006 | 0.3261 | 0.3261 |
Loa Loa (eye worm) | thymidylate kinase | 0.0145 | 1 | 1 |
Mycobacterium ulcerans | thymidylate kinase | 0.0145 | 1 | 0.5 |
Onchocerca volvulus | Putative thymidylate kinase | 0.0145 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 5.8048 uM | PubChem BioAssay. qHTS for induction of synthetic lethality in tumor cells producing 2HG: qHTS for the HT-1080-NT fibrosarcoma cell line. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 14.1254 uM | PubChem BioAssay. qHTS of GLP-1 Receptor Inverse Agonists (Inhibition Mode). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 31.6228 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b: Cytotox Counterscreen. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588855, AID588860] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.